A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults.

Trial Profile

A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Antiretrovirals; Raltegravir
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms SAILING
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 16 Nov 2017 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
    • 07 Sep 2017 Planned End Date changed from 1 Nov 2015 to 30 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top